About the Task Force
The FDA Nanotechnology Task Force (Task Force), formed in August 2006, is charged with determining regulatory approaches that encourage the continued development of innovative, safe, and effective FDA-regulated products that use nanotechnology materials. The Task Force continues to identify and recommend ways to address any knowledge or policy gaps that exist to better enable the agency to evaluate possible adverse health effects from FDA-regulated products that use nanotechnology materials.
The Task Force reports to the Chief Scientist, within the Office of the Commissioner. Task Force members are designated representatives from all FDA Centers and Offices.
- FDA Nanotechnology Report Outlines Scientific, Regulatory Challenges
- FDA Forms Internal Nanotechnology Task Force